These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 14992418)

  • 1. Safety and tolerability of fluoroquinolones.
    Sprandel KA; Rodvold KA
    Clin Cornerstone; 2003; Suppl 3():S29-36. PubMed ID: 14992418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The safety profile of the fluoroquinolones.
    Bertino J; Fish D
    Clin Ther; 2000 Jul; 22(7):798-817; discussion 797. PubMed ID: 10945507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New antibiotics for community-acquired lower respiratory tract infections: improved activity at a cost?
    Ball P
    Int J Antimicrob Agents; 2000 Nov; 16(3):263-72. PubMed ID: 11091046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial safety: focus on fluoroquinolones.
    Owens RC; Ambrose PG
    Clin Infect Dis; 2005 Jul; 41 Suppl 2():S144-57. PubMed ID: 15942881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A critical review of the fluoroquinolones: focus on respiratory infections.
    Zhanel GG; Ennis K; Vercaigne L; Walkty A; Gin AS; Embil J; Smith H; Hoban DJ
    Drugs; 2002; 62(1):13-59. PubMed ID: 11790155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Grepafloxacin: a review of its safety profile based on clinical trials and postmarketing surveillance.
    Lode H; Vogel F; Elies W
    Clin Ther; 1999 Jan; 21(1):61-74; discussion 1-2. PubMed ID: 10090425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety profile of the fluoroquinolones: focus on levofloxacin.
    Liu HH
    Drug Saf; 2010 May; 33(5):353-69. PubMed ID: 20397737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies.
    Gavin JR; Kubin R; Choudhri S; Kubitza D; Himmel H; Gross R; Meyer JM
    Drug Saf; 2004; 27(9):671-86. PubMed ID: 15230648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of trovafloxacin in treatment of lower respiratory tract infections.
    Williams D; Hopkins S
    Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):454-8. PubMed ID: 9758292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dichotomous selection of high-level oxacillin resistance in Staphylococcus aureus by fluoroquinolones.
    Dalhoff A; Schubert S
    Int J Antimicrob Agents; 2010 Sep; 36(3):216-21. PubMed ID: 20630710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections.
    Balfour JA; Lamb HM
    Drugs; 2000 Jan; 59(1):115-39. PubMed ID: 10718103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety profile of moxifloxacin and other fluoroquinolones in special patient populations.
    Iannini PB
    Curr Med Res Opin; 2007 Jun; 23(6):1403-13. PubMed ID: 17559736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac events after macrolides or fluoroquinolones in patients hospitalized for community-acquired pneumonia: post-hoc analysis of a cluster-randomized trial.
    Postma DF; Spitoni C; van Werkhoven CH; van Elden LJR; Oosterheert JJ; Bonten MJM
    BMC Infect Dis; 2019 Jan; 19(1):17. PubMed ID: 30612559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse drug reactions related to the use of fluoroquinolone antimicrobials: an analysis of spontaneous reports and fluoroquinolone consumption data from three italian regions.
    Leone R; Venegoni M; Motola D; Moretti U; Piazzetta V; Cocci A; Resi D; Mozzo F; Velo G; Burzilleri L; Montanaro N; Conforti A
    Drug Saf; 2003; 26(2):109-20. PubMed ID: 12534327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective, comparative evaluation of dysglycemias in hospitalized patients receiving gatifloxacin, levofloxacin, ciprofloxacin, or ceftriaxone.
    Mohr JF; McKinnon PS; Peymann PJ; Kenton I; Septimus E; Okhuysen PC
    Pharmacotherapy; 2005 Oct; 25(10):1303-9. PubMed ID: 16185173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of allergic reactions associated with antibacterial use in a large, managed care organisation.
    Johannes CB; Ziyadeh N; Seeger JD; Tucker E; Reiter C; Faich G
    Drug Saf; 2007; 30(8):705-13. PubMed ID: 17696583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review.
    Jones SC; Sorbello A; Boucher RM
    Drug Saf; 2011 Oct; 34(10):839-47. PubMed ID: 21879778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative tolerability of the newer fluoroquinolone antibacterials.
    Ball P; Mandell L; Niki Y; Tillotson G
    Drug Saf; 1999 Nov; 21(5):407-21. PubMed ID: 10554054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms.
    Blondeau JM; Laskowski R; Bjarnason J; Stewart C
    Int J Antimicrob Agents; 2000 Feb; 14(1):45-50. PubMed ID: 10717500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluoroquinolones or macrolides alone versus combined with β-lactams for adults with community-acquired pneumonia: Systematic review and meta-analysis.
    Raz-Pasteur A; Shasha D; Paul M
    Int J Antimicrob Agents; 2015 Sep; 46(3):242-8. PubMed ID: 26092096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.